BLT.AX - Benitec Biopharma Limited

ASX - ASX Delayed Price. Currency in AUD

Benitec Biopharma Limited

99 Mount Street
Suite 1201
North Sydney, NSW 2060
61 2 9555 6986

IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Gregory West CACEO & Company Sec.429.71kN/AN/A
Dr. David A. Suhy B.Sc., Ph.D.Chief Scientific Officer360.29kN/AN/A
Mr. Bryan DulhuntyChief Financial OfficerN/AN/AN/A
Annabel MurphyHead of Investor Relations & Corp. CommunicationsN/AN/AN/A
Dr. Michael Graham BSc (Hons), Ph.D.Head of Discovery and Founding ScientistN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology. The company was founded in 1995 and is headquartered in North Sydney, Australia.

Corporate Governance

Benitec Biopharma Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.